Since ongoing research in sJIA patients supports a disease-promoting role for IL-1β and IL-6 [69,70,71,72], a shift in treatment recommendations has been made towards IL-1 and IL-6 blockade. The gene discussed is IL6; the disease is systemic-onset juvenile idiopathic arthritis.